- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02685852
Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Roux-en-Y gastric bypass surgery (RYGB) is one of the most common bariatric surgeries in the United States and is generally highly effective for weight loss. Unfortunately, among the potential complications is hyperinsulinemic hypoglycemia. Though the prevalence of this disorder has not been fully characterized, it can be associated with debilitating symptoms which severely impact quality of life and can be life-threatening. The underlying pathophysiology of hyperinsulinemic hypoglycemia likely involves a mismatch in the amount of insulin secreted in response to mealtime carbohydrate absorption. It has been observed that the ingestion of a high carbohydrate load often leads to a modest rise in post-prandial glucose levels followed by an inappropriately exaggerated insulin release among individuals with this condition. Low carbohydrate diet sometimes provides full or partial relief of the symptoms.
Standard medical management for RYGB associated postprandial hyperinsulinemic hypoglycemia includes acarbose, which partially reduces carbohydrate absorption from the gut, and diazoxide, which directly inhibits insulin release from pancreatic beta cells. However, the medical options are not reliably effective, leading some individuals to reverse RYGB, which also may not be effective, or even undergo partial pancreatectomy, risking additional complications such as diabetes. Much more reliably effective treatments are needed for this special population who develop this bariatric surgical complication.
Potential mechanisms contributing to the mismatched insulin secretion post RYGB include decreased systemic and adipose tissue inflammation, and increased insulin receptor expression in liver and skeletal muscle, and increases in adiponectin.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- must have undergone RYGB and subsequently developed post-prandial hypoglycemia (defined as at least 3 episodes over a six-month period with documented capillary blood sugars [<60 mg/dL with hypoglycemic symptoms). Subjects may also have had a formal mixed meal tolerance test with post meal blood sugar <60 mg/dL.
- Subjects who otherwise meet the study criteria above with hypoglycemia symptoms but who do not have documented hypoglycemia by plasma measurement may undergo a screening visit to document the requisite levels for consideration into the study.
Exclusion Criteria:
- Chronic or acute diseases of the liver.
- Chronic or acute diseases of the pancreas (including type 1 diabetes or pancreatitis or a history of pancreatitis). Subjects may have a diagnosis of type 2 diabetes but must no longer require diabetes medication.
- Chronic or acute diseases of the kidneys.
- Known malignancies and must not have a family history of medullary thyroid cancer.
- History of pre-RYGB hypoglycemia symptoms or low documented plasma glucose preoperatively.
- Pregnant or plans to become pregnant throughout study duration
- Breastfeeding
- Medication exclusions in addition to the current use of diabetes medications. Subjects will be excluded if they have previously taken GLP-1 agonists.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1: Exenatide (5mcg) + Acarbose Placebo
Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose placebo immediately prior to the high-carb meal
|
Exenatide at a dose of 5 mcg
Other Names:
Placebo for Acarbose
|
Active Comparator: Arm 2: Exenatide (5mcg) + Acarbose (25mg)
Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
|
Exenatide at a dose of 5 mcg
Other Names:
Acarbose at a dose of 25 mg
|
Placebo Comparator: Arm 3: Exenatide Placebo + Acarbose (25mg)
Exenatide placebo 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
|
Acarbose at a dose of 25 mg
Placebo for Exenatide
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose area under the curve (AUC) following treatment for each 4-hour test period
Time Frame: During the 4-hour test period
|
Each time point (15, 30, 45, 60, 90, 120, 180 and 240 minutes) will be used to calculate AUC using the trapezoidal method.
|
During the 4-hour test period
|
Presence of hypoglycemia
Time Frame: 15, 30, 45, 60, 90, 120, 180 and 240 minutes
|
If at each time-point (15, 30, 45, 60, 90, 120, 180 and 240 minutes) plasma glucose is <60 mg/dL, participants will be defined as hypoglycemic
|
15, 30, 45, 60, 90, 120, 180 and 240 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Minimum post-prandial blood sugar level (mg/dL)
Time Frame: post meal test
|
The lowest post-prandial blood glucose level at any time point (15, 30, 45, 60, 90, 120, 180 and 240 minutes) may be used as the minimum post-prandial blood sugar level (mg/dL).
|
post meal test
|
Change in post-prandial blood glucose from 0min to 120min
Time Frame: 0min to 120min
|
% change in blood glucose 0min to 120min
|
0min to 120min
|
Change in post-prandial Insulin levels (mcg/mL)
Time Frame: 0min to 120min
|
% change in insulin 0min to 120min
|
0min to 120min
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shalamar D Sibley, MD, University of Minnesota
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Infant, Newborn, Diseases
- Hyperinsulinism
- Pancreatic Diseases
- Hypoglycemia
- Congenital Hyperinsulinism
- Nesidioblastosis
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Obesity Agents
- Incretins
- Glycoside Hydrolase Inhibitors
- Exenatide
- Acarbose
Other Study ID Numbers
- 1503M65841
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperinsulinemic Hypoglycemia
-
Baylor College of MedicineNo longer availableCongenital Hyperinsulinism | Hyperinsulinemic Hypoglycemia, Persistent | Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)United States
-
Dr. Tracey McLaughlin, MDEiger BioPharmaceuticalsCompletedAcquired Hyperinsulinemic HypoglycemiaUnited States
-
Children's Hospital of PhiladelphiaUniversity of PennsylvaniaCompletedPersistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI) | Congenital Hyperinsulinism (CHI)United States
-
Hospital Universitari Vall d'Hebron Research InstituteUnknownPostprandial HypoglycemiaSpain
-
University Hospital, Gentofte, CopenhagenCompletedHyperinsulinemic Hypoglycemia | Postprandial HypoglycemiaDenmark
-
Filip Krag KnopZealand PharmaActive, not recruitingHyperinsulinemic Hypoglycemia | Postprandial HypoglycemiaDenmark
-
Stanford UniversityAmerican Diabetes AssociationRecruiting
-
Lia BallyCompletedRoux-en-y Gastric Bypass | Post Prandial HypoglycemiaSwitzerland
-
Xeris PharmaceuticalsCompletedHyperinsulinemic HypoglycemiaUnited States
-
University of MinnesotaCompleted
Clinical Trials on Exenatide
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusUnited States
-
AstraZenecaCompletedType 2 Diabetes MellitusCanada, United States
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusKorea, Republic of, China, Japan, Taiwan, India
-
AstraZenecaCompletedDiabetes Mellitus, Type 2United States
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusKorea, Republic of, Mexico, Germany, Greece, Argentina, India, Australia
-
AstraZenecaEli Lilly and CompanyCompletedType 2 Diabetes MellitusUnited States
-
Beijing Chao Yang HospitalCompleted
-
AstraZenecaCelerionCompleted
-
AstraZenecaEli Lilly and CompanyCompletedType 2 DiabetesUnited States
-
University at BuffaloAmylin Pharmaceuticals, LLC.Completed